In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 661 ( 2022-09-07)
Abstract:
Patients with head and neck squamous cell carcinoma (HNSCC) often present with advanced disease that leads to a poor overall survival rate due to lack of targeted treatments. To identify new treatments, Gu et al. performed pharmacogenomics on a large resource of patient-derived cells to screen and validate compounds to identify potential biomarkers and new drug associations. They identified high expression of ITGB1 as a marker of resistance to docetaxel treatment, which they validated in a phase 2 clinical trial. This pharmacogenomic resource is an effective tool for identifying biomarkers and new targeted therapies to help improve treatment of HNSCC.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abo5987
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink